Based on the established correlation between the TLR-4 signaling pathway and tumor chemotherapy resistance, future research should delve deeper into whether abnormal TLR-4 expression can serve as an independent biomarker for assessing tumor resistance in clinical treatment. This evidence concerns the gene TLR4 and neoplasm.